Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma
Cancer Control · 2024
DOI: 10.1177/10732748241297326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Control, 2024. Verfasst von Aleena Boby und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Tampa, University of South Florida Morsani College of Medicine, Tampa, FL, USA. Hauptthemen laut MEDLINE: Melanoma, Extremities. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Ten percent of patients with melanoma develop in-transit metastases (ITM). Isolated limb infusion (ILI) is a well-established therapy for unresectable ITM on the extremities, but the ideal sequencing/line of therapy of ILI has not been defined. This study evaluates ILI as first-line, second-line, or third or later-line therapy.
Methods
A retrospective review included all patients with unresectable ITM who underwent ILI from 2006-2023.
Results
A total of 130 patients were identified, 61% female, median age of 71 (31-89) years. Median follow-up was 37.5 months. ILI was first-line therapy in 80% (n = 104), second-line in 15% (n = 19), and third or later-line in 5.4% (n = 7). Overall response rate (ORR) and complete response (CR) rates for ILI as any line of therapy were 74% and 41%, respectively. ORR for ILI as first, second, or third or later-line therapy were 78%, 63%, and 57%, respectively. CR rates for ILI as first, second, or third or later-line therapy were 42%, 37%, and 43%, respectively. There were no significant differences in ORR, progression-free survival (PFS), overall survival, or disease-free survival between therapy lines. Median PFS for ILI as first, second, or third or later-line therapy were 6.9, 5.4, and 18 months, respectively.
Conclusion
Patients responded well to ILI, whether or not they received previous therapies for unresectable ITM. First-line ILI appears to have a better ORR than later lines of ILI. Although sample size limited statistical significance, there was a 21% improvement in ORR when ILI was used as first-line vs third-line therapy, which is clinically meaningful. ILI is effective for unresectable melanoma ITM and can be used as salvage therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of South Florida Tampa, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
- Department of General Surgery, University of Massachusetts Chan Medical School, Boston, MA, USA.
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
- Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
ORCID-Profile: Michelle M Dugan, Jonathan S Zager
Zitieren
APA
Boby, A., Dugan, M. M., Ghali, H., Aflatooni, S., DePalo, D. K., Fan, W., & Zager, J. S. (2024). Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma. Cancer Control. https://doi.org/10.1177/10732748241297326
Vancouver
Boby A, Dugan MM, Ghali H, Aflatooni S, DePalo DK, Fan W, et al. Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma. Cancer Control. 2024. doi:10.1177/10732748241297326
BibTeX
@article{Boby2024,
author = {Boby, Aleena and Dugan, Michelle M and Ghali, Helana and Aflatooni, Shaliz and DePalo, Danielle K and Fan, Wenyi and Zager, Jonathan S},
title = {Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma},
journal = {Cancer Control},
year = {2024},
doi = {10.1177/10732748241297326}
}
EUVIMED